Print

Purpose

This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.

Conditions

Eligibility

Eligible Ages
Between 14 Years and 24 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosed with epilepsy - Currently prescribed anti-seizure medicine (ASMs) - Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage) - Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study - Are between 18-24 years old and able to provide informed consent - Able to read, speak, and write in English - Resides in Florida - Receive outpatient medical services

Exclusion Criteria

  • They do not own a mobile device with internet access. - They have a history of severe intellectual disability. - They are unable to operate a mobile device (keyboard or touchscreen). - Reside in an in-patient setting. - Adults unable to consent. - Pregnant women (excluded because pregnancy is not relevant to the study focus). - Prisoners.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Supportive Care
Masking
Single (Participant)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Medilepsy® Chatbot AI-Enhanced 		Participants in the intervention group will use the AI-personalized version of the Medilepsy® app.
  • Other: Medilepsy® Chatbot AI-Enhanced
    Participants in the intervention group will use the AI-personalized version of the Medilepsy® app, which includes a Smart Chatbot that delivers interactive support based on user-entered data. The chatbot offers personalized prompts, relevant topic suggestions, and adaptive educational content to support epilepsy self-management.
Active Comparator
Medilepsy® Chatbot Standard 		Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality.
  • Other: Medilepsy® Chatbot Standard
    Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality. This version includes static prompts and general educational links but does not provide personalized feedback or adaptive interaction.

Recruiting Locations

Orlando Health
Orlando, Florida 32806
Contact:
Michelle Tall, PhD, RN, FAES

University of Central Florida
Orlando, Florida 32827
Contact:
Amoy Fraser, PhD, CCRP, PMP
4072668742
Amoy.Fraser@ucf.edu

More Details

Status
Recruiting
Sponsor
University of Central Florida

Study Contact

Michelle Tall, PhD, RN, FAES
4077970555
Michelle.Tall@UCF.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.